What is Excellos?
Excellos, an entity built upon the legacy of the San Diego Blood Bank, specializes in supplying cGMP cellular products and services. The company offers crucial process development and manufacturing expertise tailored for scientists and clinicians engaged in cell and gene therapies. Its core mission is to enhance human life by providing essential products and services that support life science research and the advancement of next-generation cell and gene therapies, positioning itself as a key player in the biopharmaceutical supply chain.
How much funding has Excellos raised?
Excellos has raised a total of $15M across 1 funding round:
Other Financing Round
$15M
Other Financing Round (2022): $15M with participation from Telegraph Hill Partners
Key Investors in Excellos
Telegraph Hill Partners
Telegraph Hill Partners is a venture capital firm founded in 2001, based in San Francisco, CA, with a focus on investing in commercial-stage life science, medical technology, and healthcare companies.
What's next for Excellos?
The recent major strategic investment signals a pivotal growth phase for Excellos. This capital infusion is expected to accelerate the company's expansion of its cGMP cellular product offerings and manufacturing capabilities. With a focus on supporting the burgeoning cell and gene therapy market, Excellos is poised to deepen its impact on scientific discovery and the clinical application of innovative treatments. The company's strategic direction likely involves scaling operations to meet increasing demand and further solidifying its role as a critical partner in the biopharmaceutical ecosystem.
See full Excellos company page
